Key Insights

Highlights

Success Rate

83% trial completion

Published Results

30 trials with published results (12%)

Research Maturity

82 completed trials (34% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.0%

17 terminated out of 243 trials

Success Rate

82.8%

-3.7% vs benchmark

Late-Stage Pipeline

16%

38 trials in Phase 3/4

Results Transparency

37%

30 of 82 completed with results

Key Signals

30 with results83% success17 terminated

Data Visualizations

Phase Distribution

156Total
Not Applicable (73)
Early P 1 (4)
P 1 (9)
P 2 (32)
P 3 (11)
P 4 (27)

Trial Status

Completed82
Recruiting60
Unknown38
Not Yet Recruiting18
Terminated17
Active Not Recruiting16

Trial Success Rate

82.8%

Benchmark: 86.5%

Based on 82 completed trials

Clinical Trials (243)

Showing 20 of 20 trials
NCT05719714Phase 1Active Not Recruiting

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

NCT06081543Not ApplicableRecruitingPrimary

Ketogenic Diet vs Mixed Diet in Patients With Heart Failure

NCT05887271Phase 2CompletedPrimary

A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction

NCT05824923Phase 3Active Not Recruiting

A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

NCT06576297Not ApplicableCompleted

Novel Respiratory Training as Part of Palliative Care for Older Adults With Heart Failure

NCT04998877Active Not RecruitingPrimary

Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients

NCT07599293CompletedPrimary

Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data

NCT07202000Phase 2RecruitingPrimary

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

NCT04945707Phase 4Completed

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

NCT07083011Phase 2RecruitingPrimary

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

NCT07686692Phase 4Not Yet RecruitingPrimary

IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency

NCT05953831Phase 2WithdrawnPrimary

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

NCT06616974Phase 2Active Not Recruiting

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT07214376Not ApplicableRecruiting

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

NCT05525663Not ApplicableRecruitingPrimary

Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction

NCT07037459Phase 3RecruitingPrimary

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT05064709Not ApplicableRecruiting

Assessment of CCM in HF With Higher Ejection Fraction

NCT05839028Active Not RecruitingPrimary

Mechanisms of LV Remodeling in Hypertensive Patients Working on a Rotational Expeditionary Basis in the Arctic

NCT05562063Phase 4CompletedPrimary

Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

NCT07254455Not ApplicableNot Yet Recruiting

CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction)

Scroll to load more

Research Network

Activity Timeline